Multiple Myeloma Posts on Medivizor

Posted by Medivizor on Sep 17, 2023 in Multiple Myeloma | 0 comments

In a nutshell The study evaluated the effectiveness of combined therapy of bortezomib (Velcade), melphalan (Alkeran), and prednisone (Deltasone) with (D-VMP) versus without (VMP) daratumumab (Darzalex) in transplant-ineligible patients newly diagnosed with multiple myeloma (MM). The study concluded that D-VMP was more effective than using...

Posted by Medivizor on Jul 30, 2023 in Multiple Myeloma | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of adding isatuximab (Sarclisa) to carfilzomib (Kyprolis) and dexamethasone (Decadron) combination (Kd) for patients with previously treated relapsed multiple myeloma (MM). The data showed that over the long term adding isatuximab to the Kd regimen was effective with manageable side...

Posted by Medivizor on Apr 30, 2023 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding isatuximab (Sarclisa) to lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (Decadron) combination as induction therapy for patients with newly diagnosed transplantation-eligible multiple myeloma (MM). The data showed that the addition of isatuximab to lenalidomide,...

Posted by Medivizor on Feb 28, 2023 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness of lenalidomide (Revlimid)-containing regimens in patients with first relapsed multiple myeloma (MM). The data showed that daratumumab (Darzalex) combined with lenalidomide and dexamethasone (Rd) regimen significantly increased the survival without cancer worsening with fewer serious side effects...

Posted by Medivizor on Dec 4, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of different first-line regimens for the treatment of patients with newly diagnosed multiple myeloma (MM) ineligible for a transplant. The data showed that first-line treatment should be based on daratumumab (Darzalex)-based regimens or the VRd regimen [bortezomib (V; Velcade), lenalidomide...

Posted by Medivizor on Sep 20, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study reported the final effectiveness and safety of subcutaneous (SC) injections versus intravenous (IV) infusions of daratumumab (Darzalex) in patients with relapsed or refractory multiple myeloma (MM). The data showed that daratumumab SC injections were as effective and caused fewer side effects than IV infusions over the long term...